Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Sales and Divestitures (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $1.9 million as the latest value for Q2 2025.

  • Quarterly Gains from Sales and Divestitures rose 2170.85% to $1.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Jun 2025, up 2170.85% year-over-year, with the annual reading at $3.8 million for FY2024, 1698.06% up from the prior year.
  • Gains from Sales and Divestitures hit $1.9 million in Q2 2025 for BridgeBio Pharma, up from $879051.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $3.8 million in Q4 2024 to a low of $8057.0 in Q3 2024.
  • Historically, Gains from Sales and Divestitures has averaged $816991.1 across 5 years, with a median of $379810.5 in 2021.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 99.69% in 2024 and later surged 2170.85% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $395672.0 in 2021, then surged by 393.79% to $2.0 million in 2022, then plummeted by 89.16% to $211860.0 in 2023, then soared by 1698.06% to $3.8 million in 2024, then tumbled by 49.06% to $1.9 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for BBIO at $1.9 million in Q2 2025, $879051.0 in Q1 2025, and $3.8 million in Q4 2024.